DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS ) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 8194260. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com . The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is in a pivotal Phase 3 trial for the treatment of mRCC, and the company plans to have data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid- 2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com .
Jeffrey Abbey President & Chief Executive Officer Argos Therapeutics (919) 287-6308 Media: Andrea Coan Berry & Company Public Relations (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan (212) 213-0006